BioNTech

BioNTech’s Strategic Pivot: Merging Assets and Shifting Focus to Oncology

kashif hafeez - December 24, 2025

BioNTech Secures CureVac Acquisition Amid Market Indifference

angelina - December 19, 2025

BioNTech Shares: A Valuation Disconnect Amid Operational Progress

December 18, 2025

BioNTech’s Dual Strategy: M&A and Clinical Data Signal Oncology Shift

December 17, 2025

BioNTech’s Strategic Moves Spark Investor Reassessment

December 15, 2025

Institutional Investors Seize Opportunity in BioNTech’s Depressed Shares

angelina - December 13, 2025

Analysts See Significant Upside for BioNTech Shares

December 13, 2025

BioNTech Shares Navigate Sector Headwinds Amid Clinical Progress

angelina - December 11, 2025

BioNTech Clears Major Acquisition Milestone Amid Sector Headwinds

December 6, 2025

BioNTech Clears Final Hurdle in CureVac Acquisition

kashif hafeez - December 5, 2025

BioNTech Consolidates mRNA Leadership with CureVac Acquisition Finalized

angelina - December 4, 2025

Regulatory Headwinds Rattle BioNTech and Vaccine Sector

Brett Shapiro - December 2, 2025

BioNTech Shares Plunge Amid Regulatory Concerns

angelina - December 1, 2025

BioNTech Clears Major Hurdle in Strategic Acquisition

November 27, 2025

BioNTech Shares Face Critical Test Amid Strategic Shifts

angelina - November 26, 2025

1 234 Page 3 of 4